Nabriva Therapeutics to Participate in Two Investor Conferences in May

DUBLIN, Ireland and KING OF PRUSSIA, Pa. , April 25, 2018 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin

READ FULL TEXT

Leave a Reply

Your email address will not be published.